Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells

Chinese Journal of Cancer

Volumn 31, Issue 2, 2012, Pages 110-118

  Peng, Xing Xiang ^a,b   Tiwari, Amit K ^a,c   Wu, Hsiang Chun ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drug transporters; Human chronic myelogenous leukemia; Imatinib; Multidrug resistance; P glycoprotein

Indexed keywords

BCR ABL PROTEIN; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER RESISTANCE; CELL TRANSPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MULTIDRUG RESISTANCE PROTEIN 1 GENE; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; METHOTREXATE; P-GLYCOPROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, MESSENGER;

EID: 84863260456     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10327     Document Type: Article

References (47)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973,243:290-293.
2. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med, 2003,349:1451-1464.
3. Hehlmann R, Hochhus A, Baccarani M. Chronic myeloid leukemia. Lancet, 2007,370:342-350.
4. Roskoski R Jr. STI-57 1: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun, 2003,309:709-717.
5. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol, 2006,57:145-164.
6. Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell, 2002,1:13-15.
7. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene, 2003,22:7389-7395.
8. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996,2:561-566.
9. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-A BL-positive cells. Blood, 1997,90:3691-3698.
10. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of Bcr/Abl +leukemic cells and induces apoptosis. Blood Cells Mol Dis, 1997,23:380-394.
11. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002,346:645-652.
12. O'Brien SG, Guilhot F, Larson RA, et al. Investigators. Imatinib compared with interferon and low-dosecytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med, 2003,348:994-1004.
13. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-A BL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med, 2001,344:1038-1042.
14. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat, 2001,4:22-28.
15. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet, 2003,4:75-85.
16. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene over expression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 2003,101:2368-2373.
17. Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood, 2003,102:1142.
18. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-sp ecific drug binding. Science, 2009,323:1718-1722.
19. Dai H, Marbach P, Lemaire M, et al. Distribution of STI-57 1 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther, 2003,304:1085-1092.
20. Hegdus T, Orfi L, Septodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta, 2002,1587:318-325.
21. Mukai M, Che XF, Furukawa T, et al. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci, 2003,94:557-563.
22. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia, 2004,18:401-408.
23. Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesylate with human p-glycoprotein. J Pharmacol Exp Ther, 2003,307:824-828.
24. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004,104:2940-2942.
25. Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther, 2005,4:747-752.
26. Ferrao PT, Frost MJ, Siah SP, et al. Over expression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood, 2003,102:4499-4503.
27. Hirayama C, Watanabe H, Nakashima R, et al. Constitutive over expression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res, 2008,25:827-835.
28. Peng XX, Shi Z, Damaraju VL, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res, 2008,32:799-809.
29. Zeng H, Lin ZP, Sartorelli AC. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochem Pharmacol, 2004,68:911-921.
30. Breuninger LM, Paul S, Gaughan K, et al. Expression of multi drug associated protein in NIH/3T3 cells confers multi drug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res, 1995,55:5342-5347.
31. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D -glucuronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem, 2001,276:33747-33754.
32. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst, 2000,92:1934-1940.
33. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D -glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res, 2003,63:4048-4054.
34. Peng XX, Li YB. Induction of cellular glutathione-linked enzymes and catalase by the unique chemoprotective agent, 3H -1, 2-di thiole-3- thione in rat cardiomyocytes affords protection against oxidative cell injury. Pharmacol Res, 2002,45:491-497.
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976,72:248-254.
36. Assef Y, Rubio F, Colo G, et al. Imatinib resistance in multi drug-resistant K562 human leukemic cells. Leuk Res, 2009,33:710-716.
37. Peng XX, Shi Z, Tiwari, et al. Up-regulation of P-glycoprotein confers acquired resistance to 6-m ercaptopurine in human chronic myeloid leukemia cells. Oncol Lett, 2011,2(3):549-556.
38. Hart SM, Ganeshaguru K, Hoffbrand AV, et al. Expression of the Multi drug resistance-as sociated protein (MRP) in acute leukemia. Leukemia, 1994,8:2163-2168.
39. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica, 2000,85:711-721.
40. Kuwazuru Y, Yoshimura A, Hanada S, et al. Expression of multidrug transporter-glycoprotein, in chronic myelogenous leukemia cells in blast crisis. Br J Haematol, 1990,74:24-29.
41. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx, 2005,2:86-98.
42. De Graaf D, Sharma RC, Mechetner EB, et al. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA, 1996,93:1238-1242.
43. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica, 2008,93:161-169.
44. Jiang X, Saw KM, Eaves A, et al. Instability of BCR-A BL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst, 2007,99:680-693.
45. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 2000,95:1758-1766.
46. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol, 2009,27:469-471.
47. Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem, 2010,285:21446-21457.